A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.
Breast Neoplasms
DRUG: LY2835219|DRUG: Letrozole|DRUG: Anastrozole|DRUG: Tamoxifen|DRUG: Exemestane|DRUG: Everolimus|DRUG: Trastuzumab|DRUG: LY3023414|DRUG: Fulvestrant|DRUG: Pertuzumab|DRUG: Loperamide|DRUG: Endocrine therapy
Number of Participants with One or More Drug-Related Adverse Events, Number of participants with one or more drug-related adverse events, Baseline through study completion (estimated as 12 months)
Pharmacokinetics: Maximum Concentration (Cmax) of LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, Fulvestrant, and Pertuzumab, Cmax of LY2835219, letrozole, anastrozole, tamoxifen, exemestane, everolimus, trastuzumab, LY3023414, fulvestrant, and pertuzumab., Cycle 1 up to Cycle 5 (21 or 28 Day Cycle): Predose and at multiple timepoints, depending on study part.|Number of Participants with a Complete or Partial Tumor Response (Overall Response Rate), Number of participants with a complete or partial tumor response (overall response rate)., Baseline to study completion (estimated as 12 months)|Progression Free Survival (PFS), Progression free survival, First dose to progressive disease or death of any cause (estimated as 12 months)|Change in MD Anderson Symptom Inventory (MDASI) Score from Baseline, Change in MD Anderson (MDASI) score from baseline., Baseline, through study completion (estimated as 12 months)|Pharmacokinetics: Area under the Curve (AUC) of LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, Fulvestrant, and Pertuzumab, Pharmacokinetics: AUC of LY2835219, letrozole, anastrozole, tamoxifen, exemestane, everolimus, trastuzumab, LY3023414, fulvestrant, and pertuzumab., Cycle 1 up to Cycle 5 (21 or 28 Day Cycle): Predose and at multiple timepoints, depending on study part.
This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.